Suven Life Sciences rose 4.14% to Rs 209 at 11:26 IST on BSE after net profit rose 58.2% to Rs 32.58 crore on 31.7% rise in net sales to Rs 133.23 crore in Q1 June 2016 over Q1 June 2015.
The result was announced after market hours yesterday, 10 August 2016.Meanwhile, the BSE Sensex was up 86.64 points, or 0.31%, to 27,861.52.
On BSE, so far 1.20 lakh shares were traded in the counter, compared with average daily volume of 60,192 shares in the past one quarter. The stock hit a high of Rs 213.90 and a low of Rs 206.15 so far during the day. The stock hit a 52-week high of Rs 308.70 on 5 October 2015. The stock hit a 52-week low of Rs 144.35 on 19 February 2016. The stock had underperformed the market over the past 30 days till 10 August 2016, falling 2.43% compared with 0.12% decline in the Sensex. The scrip had also underperformed the market in past one quarter, sliding 5.24% as against Sensex's 7.70% rise.
The small-cap company has equity capital of Rs 12.73 crore. Face value per share is Re 1.
Suven Life Sciences' earnings before interest, taxes, depreciation and amortization (EBITDA) rose 56.34% to Rs 47.90 crore in Q1 June 2016 over Q1 June 2015. EBITDA margins were reported at 34.80% in Q1 June 2016, higher than 28.84% in Q1 June 2015.
The company said that its thrust on innovative research and development (R&D) in drug discovery continues with a spending of Rs 14.70 crore (10.67% on revenue) in Q1 June 2016.
Suven Life Sciences is a biopharmaceutical company specializing in drug discovery and developmental activities in central nervous system disorders and contract research and manufacturing services (CRAMS).
Powered by Capital Market - Live News
